🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSemaglutide (Ozempic / Wegovy)A1C reduction on semaglutide: SUSTAIN program meta-analysis — anyone have experience?

A1C reduction on semaglutide: SUSTAIN program meta-analysis — anyone have experience?

BethLabQueen Tue, Nov 4, 2025 at 9:33 AM 11 replies 1,280 viewsPage 1 of 3
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
Nov 4, 2025 at 9:33 AM#1

Collecting this in one place because it comes up every few weeks and the answer is always assembled from scratch. It is about semaglutide, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

The condition it depends on

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

The practical version

Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

What I am not sure about

What I am after is how much of the between-person variation is pharmacokinetic and how much is just adherence measured badly. Numbers rather than impressions, if you have them.

— BethLabQueen · corrections welcome and will be edited into this post with credit
11 6maya_sedona, stefan_berlin, Dr.EM_Chicago and 8 others
Reply Quote Save Share Report
MikeFit_NJ
Senior Member
1,567
6,543
Apr 2024
New Jersey
Nov 4, 2025 at 11:02 AM#2
BethLabQueen said:
The dose-response is real but shallow at the top.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

10 5marcus_mpls, DeniseRN_TPA, SandraNC_45 and 7 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Nov 4, 2025 at 12:31 PM#3
BethLabQueen said:
The dose-response is real but shallow at the top.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

9 4LibrarianMeg, bri_stats, pete_manc_UK and 6 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
CarlaRPh_TPA
Senior Member
1,890
8,234
Jan 2024
Tampa, FL
Nov 4, 2025 at 2:00 PM#4

This one has a reasonably settled answer, so here it is. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

8 3labquiet_amy, emily_PDX, Dr.SleepRoch and 5 others
Reply Quote Save Share Report
kevin_tulsa
Member
489
2,123
Jun 2024
Tulsa, OK
Nov 4, 2025 at 10:41 PM#5
MikeFit_NJ said:
Agreed, though "tolerable" needs defining.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Last edited: Nov 5, 2025 at 12:41 AM
7 2NurseLeah_Nash, gary_naperville, sean_dublin and 4 others
Reply Quote Save Share Report

Similar Threads

STEP 1-5 trials comprehensive summary — efficacy endpoints compiled12 replies
Oral semaglutide 50mg Phase 3 — OASIS program results16 replies
Semaglutide pharmacokinetics — half-life, Tmax, steady state modeling10 replies
Compounded semaglutide stability data — temperature and light sensitivity16 replies
0.25mg → 2.4mg titration: optimal schedule based on clinical data6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register